Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
$12.46
-$0.14(-3.78%)
At close: 4:00 PM EST
$12.46
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$2.60 - $16.96
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.76M
Market Cap
$1.41B
Enterprise ValueN/A
Total Cash (Recent Filing)$343.99M
Total Debt (Recent Filing)$5.93M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Apr 01, 2026EPS Estimate
-0.35Last Dividend Ex-Date
Mar 28, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding106,667,435
10 Day Avg. Volume1,269,392
30 Day Avg. Volume1,759,353
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.56
Price to Sales (P/S)2.95
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$20.00Price Target Upside60.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionAmylyx reported Q3 earnings, finishing the period with $344.0M in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.
Market OpportunityEven with conservative patient estimates, the total market opportunity for a new therapy for PBH could easily exceed several billion dollars.
Therapy DevelopmentAvexitide could enter a potentially large market as the first FDA-approved treatment option for PBH.
Bears Say
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $2.60 and its highest was $16.96 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $1.41B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Apr 01, 2026 which is in 143 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.436 by $0.066.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.35.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 106,667,435 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.436. Following the earnings report the stock price went down -5.891%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (60.51% Upside)
$20.00 (60.51% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 996.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.32%
12-Months-Change
Fundamentals
Return on Equity
-56.52%
Trailing 12-Months
Asset Growth
-41.41%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with a primary emphasis on conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The company is committed to advancing its lead product, AMX0035, which aims to slow the progression of neurodegenerative disorders by targeting multiple pathways involved in cellular stress and neuroinflammation. Through its scientific expertise and dedication to addressing unmet medical needs, Amylyx is positioned at the forefront of neurotherapeutics.
AMLX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong financial performance and progress across multiple programs. However, there is a noted delay in the LUCIDITY trial enrollment, indicating some operational challenges. The urgency and unmet need in the PBH market further underscore the importance of avexitide's development.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$20.00
▲(60.51% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
7.68% Insiders
9.20% Mutual Funds
0.02% Other Institutional Investors
69.87% Public Companies and
Individual Investors